Heart Failure Clinical Trial

Low Level Tragus Stimulation in Acute Decompensated Heart Failure

Summary

Acute Decompensated Heart Failure (ADHF) is a major cause of morbidity and mortality. It is associated with increased systemic inflammation. Previous studies have demonstrated increased levels of cytokines such as C-reactive protein (CRP), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-10 (IL-10) and Tumor Necrosis Factor alpha (TNFα) in patients with heart failure (HF). Increased activity of sympathetic nervous system in ADHF is linked to inflammation. Previous anti-inflammatory drug therapies in HF have demonstrated no significant impact on cardiovascular outcomes. Low-level vagus nerve stimulation (LLVNS) is a non-invasive way to modulate autonomic tone and thereby inflammation. Vagal nerve stimulation is thought to increase the parasympathetic activity and suppress the sympathetic activity. Clinical studies of vagal stimulation in chronic HF have been negative. Recent experimental and clinical data suggest that low level tragus nerve stimulation (LLTNS) may produce the same desired neuromodulator effect compared to LLVNS. It is however unknown if LLTNS in ADHF will directly lead to a reduction in the levels of pro-inflammatory cytokines (CRP, IL-1, IL-6 and TNF-α) and an increase in the level of anti-inflammatory marker IL-10.The objective of this proposal is to determine the impact of LLTS on inflammatory cytokines in patients with ADHF.

Patients will be randomized to either active or no stimulation(~8 hours daily). Serum collected will (post admission and on days 2, 3 and 4 post admission) will be used for cytokine measurement. This investigation will likely establish the first evidence of effects of LLTS on suppression of inflammation in patients presenting with ADHF.

View Full Description

Full Description

Acute Decompensated Heart Failure (ADHF) is a major cause of morbidity and mortality. It is associated with increased systemic inflammation and poor outcomes.

Previous studies have demonstrated increased inflammation in patients with heart failure (HF). Increased activity of sympathetic nervous system in ADHF is linked to inflammation. Previous anti-inflammatory drug therapies in HF have demonstrated no significant impact on cardiovascular outcomes.

Low-level vagus nerve stimulation via stimulation of teh Tragus (LLTS) is a non-invasive way to modulate autonomic tone and thereby inflammation. Vagal nerve stimulation is thought to increase the parasympathetic activity and suppress the sympathetic activity. Recent experimental and clinical data suggest that low level tragus nerve stimulation (LLTS) may produce the same desired neuromodulator effect compared to LLVNS.

It is however unknown if LLTS in ADHF will directly lead to sympathetic tone reduction and increase in parasympathetic tone, or neuromodulation and lead to reduction in the levels of pro-inflammatory cytokines (CRP, IL-1, IL-6 and TNF-α) and an increase in the level of anti-inflammatory marker IL-10.

Autonomic tone could be assessed using heart rate variability. The objective of this proposal is to determine the impact of LLTS on inflammatory cytokines and HRV in patients with ADHF.

Patients will be randomized to either active or sham stimulation (2 hours daily).

Serum collected will (post admission and discharge day) will be used for cytokine and biomarker measurement. We will also measure 10-15 minute ECG to assess HRV. Dyspnea will be determined using patient assessment tool(visual analog scale).This investigation will likely establish the first evidence of effects of LLTS on suppression of inflammation and improvement in dyspnea scale, renal function and HRV in patients presenting with ADHF.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients admitted with ADHF

Exclusion Criteria:

Refusal to consent
Complex congenital heart disease (Tetralogy of Fallot patients, single ventricle physiology)
Recurrent vaso-vagal syncopal episodes
Unilateral or bilateral vagotomy
Sick sinus syndrome
2nd or 3rd degree AV block
bifascicular block or prolonged 1st degree AV block (PR>300ms)
Pregnant patients
Prisoners
Advanced renal dysfunction(defined as eGFR < 30, stage 4 or 5 chronic kidney disease)
Hepatitis C or HIV
Acute Myocardial infarction

Study is for people with:

Heart Failure

Estimated Enrollment:

100

Study ID:

NCT02898181

Recruitment Status:

Recruiting

Sponsor:

University of Oklahoma

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

OUHSC
Oklahoma City Oklahoma, 73104, United States More Info
Tarun Dasari
Contact
405-271-4742
[email protected]
Michael Stout
Contact
4052714742
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Estimated Enrollment:

100

Study ID:

NCT02898181

Recruitment Status:

Recruiting

Sponsor:


University of Oklahoma

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.